Sorrento Therapeutics, Inc.
| Nasdaq: SRNE
Sorrento Therapeutics, Inc. is a development stage biopharmaceutical company engaged in the discovery, development and commercialization of novel, proprietary drug candidates for the treatment of patients suffering from a variety of conditions, including cancer, inflammation, metabolic and infectious diseases. The company's primary therapeutic focus is oncology but it is also developing therapeutic products for other indications, including inflammation, metabolic, and infectious diseases. Sorrento Therapeutics' proprietary G-MAB fully-human antibody library platform was designed to facilitate the rapid identification and isolation of highly specific antibody therapeutic product candidates that bind to disease targets appropriate for antibody therapy. Sorrento's pipeline includes a portfolio of fully human therapeutic antibodies selected from the proprietary G-MAB antibody library as well as antibody-formulated drug conjugates (AfDC) and antibody drug conjugates (ADC) for indications in oncology and other diseases. Sorrento also has a proprietary recombinant intravenous immunoglobulin (rIVIG) technology that leverages the G-MAB library for the production of novel and highly differentiated IVIG products. The company was founded in 1989 and is headquartered in San Diego, CA.